Consist with our studies, multiple studies have revealed that genomic alterations in CDKN2A was the most commonly phenomenon in cancers,[23,24] including neck cancers (50%), pancreatic and esophageal cancers (47%), gliomas (35%), implying the correlation between CDKN2A alterations and tumors. This evidence concerns the gene CDKN2A and glioma.